<DOC>
	<DOCNO>NCT00141323</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness 2 dos investigational drug , lasofoxifene , compare placebo ( inactive substance ) reduce new spinal fracture woman osteoporosis .</brief_summary>
	<brief_title>Postmenopausal Evaluation Risk-reduction With Lasofoxifene ( PEARL )</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<criteria>Postmenopausal least 5 year ; Screening bone mineral density equal 2.5 S.D.s mean young adult lumbar spine femoral neck . Metabolic bone disease osteoporosis ; Taking approve medication osteoporosis ; Have recent osteoporotic fracture ( within 1 year ) and/or bone mineral density 4.5 S.D.s mean young adult lumbar spine femoral neck .</criteria>
	<gender>Female</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>